Updates in the Management of Locally Advanced Rectal Cancer

Presented by:
Christopher G. Willett
Search for other papers by Christopher G. Willett in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

A plethora of advancements in the management of locally advanced rectal cancer continue to be developed. Treatment strategies have primarily focused on modifying the current standard paradigm of rectal cancer management—including the complete omission of surgery or radiotherapy, or instead using immunotherapy as first-line treatment in eligible patients. Recommendations for optimal therapeutic strategies, based on a patient’s clinical stage, have been outlined in the NCCN Guidelines for Rectal Cancer.

Disclosures: Dr. Willett has disclosed no relevant financial relationships.

Correspondence: Christopher G. Willett, MD, Duke Cancer Institute, 30 Duke Medicine Circle, Room 05143 Morris, Box 3085, Durham, NC 27710. Email: christopher.willett@duke.edu
  • Collapse
  • Expand
  • 1.

    Holyoke ED, Mittelman A, Panahon A, et al. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:14651472.

  • 2.

    Pahlman L, Glimelius B. Local recurrence rate in a randomized multicentre trial of preoperative radiotherapy compared to surgery alone in resectable rectal carcinoma. Eur J Surg 1996;162:397402.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Abraha I, Aristei C, Palumbo I, et al. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. Cochrane Database Syst Rev 2018;10:CD002102.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Conroy T, Lamfichekh N, Etienne PL, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol 2020;38(Suppl):Abstract 4007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Hospers G, Bahadoer RR, Dijkstra EA, et al. Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: the randomized RAPIDO trial. J Clin Oncol 2020;38(Suppl):Abstract 4006.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Jin J, Tang Y, Hu C, et al. A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): the final reports. J Clin Oncol 2021;39(Suppl):Abstract 3510.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022;40:25462556.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Deng Y, Chi P, Lan P, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol 2019;37:32233233.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Schrag D, Shi Q, Weiser MR, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med 2023;389:322324.

  • 10.

    Basch E, Dueck AC, Mitchell SA, et al. Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT trial (Alliance N1048). J Clin Oncol 2023;41:37243734.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386:23632376.

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1200 1200 189
PDF Downloads 531 531 17
EPUB Downloads 0 0 0